Top

Published in:

01-03-2021 | Cytostatic Therapy | Original Article

Irinotecan-induced intestinal mucositis in mice: a histopathological study

Authors: Thaise Boeing, Marcelo Biondaro Gois, Priscila de Souza, Lincon Bordignon Somensi, Débora de Mello Gonçales Sant´Ana, Luisa Mota da Silva

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2021

Abstract

Purpose

Intestinal mucositis is an important adverse effect of antineoplastic therapy, which remains without adequate treatment. The present study aimed to carry out a complete evaluation of the histopathological changes during irinotecan-induced intestinal mucositis, using the protocol most found in the pharmacological reports nowadays to better understand irinotecan toxicity and support future studies on drug discovery.

Methods

Intestinal mucositis was induced by treating swiss mice for 4 days with irinotecan (75 mg/kg, i.p.). After 72 h post irinotecan, the mice were sacrificed and the small intestine and colon were excised to performed histological analysis by stained tissue with hematoxylin/eosin (H&E).

Results

Histoarchitecture loss, villus/crypt ratio reduction, atrophy of the muscular layer, hypertrophy in the submucosal and mucous layers, ruptures in the epithelium, as well as extent cellular infiltrate and presence of micro abscesses and the fusion of the crypts were observed in the histological analysis. Moreover, duodenum and colon had increased intraepithelial lymphocytes and mitotic figures. However, submucosal ganglia were decreased in the duodenum and increased in the colon.

Conclusions

The data obtained in the present study provides new evidence that irinotecan-induced intestinal mucositis highly affects small intestine and colon, further contributing to establish criteria in light of the histopathological changes induced by irinotecan during intestinal mucositis and facilitating inter-study comparisons.

Sangild PT, Shen RL, Pontoppidan P, Rathe M (2018) Animal models of chemotherapy-induced mucositis: translational relevance and challenges. Am J Physiol Liver Physiol 314:G231–G246. https://doi.org/10.1152/ajpgi.00204.2017CrossRef

Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann Oncol Off J Eur Soc Med Oncol 8:837–855CrossRef

Fujita KI, Kubota Y, Ishida H, Sasaki Y (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21:12234–12248. https://doi.org/10.3748/wjg.v21.i43.12234CrossRefPubMedPubMedCentral

Bajic JE, Johnston IN, Howarth GS, Hutchinson MR (2018) From the bottom-up: chemotherapy and gut-brain axis dysregulation. Front BehavNeurosci 12:104. https://doi.org/10.3389/fnbeh.2018.00104CrossRef

Potten CS, Wilson JW, Booth C (1997) Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells 15:82–93. https://doi.org/10.1002/stem.150082CrossRefPubMed

Vanhoecke B, Bateman E, Mayo B et al (2015) Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. Exp Biol Med 240:725–741. https://doi.org/10.1177/1535370215581309CrossRef

Wardill HR, Gibson RJ, Van Sebille YZA et al (2016) Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Mol Cancer Ther 15:1376–1386. https://doi.org/10.1158/1535-7163.MCT-15-0990CrossRefPubMed

Andreyev J, Ross P, Donnellan C et al (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 15:e447–e460. https://doi.org/10.1016/S1470-2045(14)70006-3CrossRefPubMed

Boeing T, de Souza P, Speca S et al (2020) Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties. Br J Pharmacol 177:2393–2408. https://doi.org/10.1111/bph.14987CrossRefPubMed

10.

Alvarenga EM, Sousa NA, de Araújo S et al (2017) Carvacryl acetate, a novel semisynthetic monoterpene ester, binds to the TRPA1 receptor and is effective in attenuating irinotecan-induced intestinal mucositis in mice. J Pharm Pharmacol 69:1773–1785. https://doi.org/10.1111/jphp.12818CrossRefPubMed

11.

Cechinel-Zanchett CC, Boeing T, Somensi LB et al (2019) Flavonoid-rich fraction of Bauhinia forficata Link leaves prevents the intestinal toxic effects of irinotecan chemotherapy in IEC-6 cells and in mice. Phyther Res 33:90–106. https://doi.org/10.1002/ptr.6202CrossRef

12.

Arifa RDN, De PTP, Madeira MFM et al (2016) The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan. Pharmacol Res 107:102–110. https://doi.org/10.1016/j.phrs.2016.03.004CrossRefPubMed

13.

Guo S, Gillingham T, Guo Y et al (2016) Secretions of bifiodobacteriuminfantis and lactobacillus acidophilus protect intestinal epithelial barrier function. J PediatGastroenterolNutr 64(3):404–412

14.

Gibson RJ, Bowen JM, Inglis MRB et al (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18:1095–1100. https://doi.org/10.1046/j.1440-1746.2003.03136.xCrossRefPubMed

15.

Logan RM, Gibson RJ, Bowen JM et al (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62:33–41. https://doi.org/10.1007/s00280-007-0570-0CrossRefPubMed

16.

Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic mucosal changes in the mouse Ileum and Cecum. JNCI 87:1876–1883CrossRef

17.

Taha AS, Dahill S, Nakshabendi I et al (1993) Duodenal histology, ulceration, and Helicobacter pylori in the presence or absence of non-steroidal anti-inflammatory drugs. Gut 34:1162–1166. https://doi.org/10.1136/gut.34.9.1162CrossRefPubMedPubMedCentral

18.

Erben U, Loddenkemper C, Doerfel K et al (2014) A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol 7:4557–4576PubMedPubMedCentral

19.

Cherny NI (2008) Evaluation and management of treatment-related Diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage 36:413–423. https://doi.org/10.1016/J.JPAINSYMMAN.2007.10.007CrossRefPubMed

20.

Cheroutre H, Lambolez F, Mucida D (2011) The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol 11:445–456CrossRef

21.

Hoytema van Konijnenburg DP, Reis BS, Pedicord VA et al (2017) Intestinal epithelial and intraepithelial T cell crosstalk mediates a dynamic response to infection. Cell 171:783-794.e13. https://doi.org/10.1016/j.cell.2017.08.046CrossRefPubMedPubMedCentral

22.

Fang ZZ, Zhang D, Cao YF et al (2016) Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression. Toxicol Appl Pharmacol 291:21–27. https://doi.org/10.1016/j.taap.2015.12.003CrossRefPubMed

23.

Fernandes C, Wanderley CWS, Silva CMS et al (2018) Role of regulatory T cells in irinotecan-induced intestinal mucositis. Eur J Pharm Sci 115:158–166. https://doi.org/10.1016/j.ejps.2018.01.006CrossRefPubMed

24.

Stringer AM, Gibson RJ, Bowen JM et al (2009) Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 90:489–499. https://doi.org/10.1111/j.1365-2613.2009.00671.xCrossRefPubMedPubMedCentral

25.

Sonis ST (2004) The pathobiology of mucositis. J NeuropatholExpNeurol 4:277–284. https://doi.org/10.1038/nrc1318CrossRef

26.

Goyal R, Guo Y, Mashimo H (2019) Advances in the physiology of gastric emptying. Neurogastroenterol Motil 31:e13546CrossRef

27.

Thorpe D, Butler R, Sultani M et al (2019) Irinotecan-Induced mucositis is associated with goblet cell dysregulation and neural cell damage in a tumour bearing da rat model. PatholOncol Res. https://doi.org/10.1007/s12253-019-00644-xCrossRef

Title: Irinotecan-induced intestinal mucositis in mice: a histopathological study
Authors: Thaise Boeing
Marcelo Biondaro Gois
Priscila de Souza
Lincon Bordignon Somensi
Débora de Mello Gonçales Sant´Ana
Luisa Mota da Silva
Publication date: 01-03-2021
Publisher: Springer Berlin Heidelberg
Keyword: Cytostatic Therapy
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2021
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-020-04186-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2021

A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects

Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation

BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series

Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed

Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer

Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer